Equities Analysts Issue Forecasts for LivaNova PLC’s FY2023 Earnings (NASDAQ:LIVN)

Share on StockTwits

LivaNova PLC (NASDAQ:LIVN) – Jefferies Financial Group issued their FY2023 earnings per share estimates for LivaNova in a note issued to investors on Wednesday, July 31st. Jefferies Financial Group analyst R. Denhoy anticipates that the company will post earnings per share of $4.69 for the year.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.59 by ($0.03). The company had revenue of $277.20 million during the quarter, compared to analysts’ expectations of $275.14 million. LivaNova had a positive return on equity of 8.56% and a negative net margin of 23.86%. The company’s revenue for the quarter was down 3.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.96 EPS.

A number of other brokerages have also recently weighed in on LIVN. Needham & Company LLC set a $91.00 price target on LivaNova and gave the stock a “buy” rating in a research note on Wednesday, July 31st. ValuEngine raised LivaNova from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Piper Jaffray Companies reaffirmed a “buy” rating on shares of LivaNova in a research note on Wednesday, July 31st. BidaskClub raised LivaNova from a “hold” rating to a “buy” rating in a research note on Friday, August 2nd. Finally, BTIG Research reaffirmed a “hold” rating on shares of LivaNova in a research note on Wednesday, July 31st. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $104.17.

Shares of LIVN opened at $78.68 on Monday. The business has a 50-day moving average of $73.68. The stock has a market cap of $3.82 billion, a PE ratio of 29.15, a P/E/G ratio of 3.32 and a beta of 0.56. LivaNova has a 1-year low of $64.80 and a 1-year high of $131.54. The company has a debt-to-equity ratio of 0.15, a current ratio of 0.95 and a quick ratio of 0.67.

In other LivaNova news, CEO Damien Mcdonald sold 1,000 shares of LivaNova stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $73.58, for a total transaction of $73,580.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Thad Allen Huston sold 2,000 shares of LivaNova stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $75.00, for a total value of $150,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,300 shares of company stock worth $387,999. Company insiders own 0.41% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in LIVN. Oakbrook Investments LLC acquired a new stake in shares of LivaNova during the 2nd quarter valued at about $245,000. FTB Advisors Inc. acquired a new stake in shares of LivaNova during the 1st quarter valued at about $216,000. Retirement Systems of Alabama lifted its holdings in shares of LivaNova by 0.5% during the 1st quarter. Retirement Systems of Alabama now owns 63,376 shares of the company’s stock valued at $6,163,000 after buying an additional 303 shares during the last quarter. Strs Ohio lifted its holdings in shares of LivaNova by 1.1% during the 1st quarter. Strs Ohio now owns 18,700 shares of the company’s stock valued at $1,818,000 after buying an additional 200 shares during the last quarter. Finally, Creative Financial Designs Inc. ADV acquired a new stake in shares of LivaNova during the 1st quarter valued at about $29,000. 83.95% of the stock is currently owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV?) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.

Further Reading: Should You Consider an Index Fund?

Earnings History and Estimates for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Sigma Planning Corp Invests $214,000 in SPDR Portfolio S&P 500 Growth ETF
Sigma Planning Corp Invests $214,000 in SPDR Portfolio S&P 500 Growth ETF
IPG Photonics Co.  Shares Sold by Swiss National Bank
IPG Photonics Co. Shares Sold by Swiss National Bank
Brokerages Set Avid Technology, Inc.  Target Price at $9.17
Brokerages Set Avid Technology, Inc. Target Price at $9.17
Intercontinental Wealth Advisors LLC Has $524,000 Stock Holdings in Exxon Mobil Co.
Intercontinental Wealth Advisors LLC Has $524,000 Stock Holdings in Exxon Mobil Co.
Brokerages Set BRT Apartments Corp  Price Target at $13.50
Brokerages Set BRT Apartments Corp Price Target at $13.50
Amazon.com, Inc.  is Truehand Inc’s Largest Position
Amazon.com, Inc. is Truehand Inc’s Largest Position


© 2006-2019 Ticker Report